Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Market Cap	2.15B
Revenue (ttm)	1.17B
Net Income (ttm)	-68.61M
Shares Out	76.92M
EPS (ttm)	-1.54
PE Ratio	n/a
Forward PE	n/a
Dividend	0.19 (0.68%)
Ex-Dividend Date	Jul 24, 2025

Volume	57,576
Average Volume	75,599
Open	27.75
Previous Close	27.95
Day's Range	27.55 - 27.90
52-Week Range	23.50 - 43.70
Beta	0.41
RSI	43.38
Earnings Date	Nov 10, 2025

About TPE:1762

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxant...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1964
• Employees: 198
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1762

Financial Performance

In 2024, TPE:1762's revenue was 1.35 billion, a decrease of -35.42% compared to the previous year's 2.09 billion. Earnings were 53.03 million, a decrease of -79.98%.